Browse Videos

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.

Susan Spratt, MD, senior medical director, Duke Population Health Management Office, breaks down the the prevalence of diabetes in the United States and discusses current diabetes initiatives at Duke Health.

This London-based charity intervenes in the short term when its clients come up against roadblocks that prevent ready access to good levels of nutrition, whether that crisis is nutritional, physical/mental health, housing, or financial related.

With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.

Clinicians are finding that there really is no basis to recommend probiotics for patients with Clostridioides difficile infection, that instead they may cause harm, said Colleen R. Kelly, MD, FACG, gastroenterologist and associate professor of medicine at The Warren Alpert Medical School of Brown University.

Differentiated service delivery models can be employed to incorporate other chronic disease needs for patients with HIV, emphasized Helen Bygrave, MD, Médecins Sans Frontières (Doctors Without Borders).

Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.

Having one of the lowest adult HIV prevalence rates in the world is a significant public health success story, explained Jason Myers, PhD, CEO of the New Zealand AIDS Foundation.

Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.

Being a full-service dermatology practice helps make patients' lives easier when they have skin cancer, explained Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

There was a reduction in both the need for dialysis and progression to end-stage renal disease; finerenone was really well tolerated, stated Bertram Pitt, MD, professor of medicine emeritus, University of Michigan School of Medicine.

With finerenone being a targeted therapy, data show there may be an additive cardiorenal benefit when it is coadministered with a sodium glucose co-transporter 2 inhibitor, noted Dipti Itchhaporia, MD, FACC, FAHA, FESC, president of the American College of Cardiology.

Whatever your theory of heart failure with preserved ejection fraction, sodium glucose co-transporter 2 (SGLT2) inhibitors seem to be attacking every one, noted Javed Butler, MD, MPH, MBA, University of Mississippi.

Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

The composite end point of cardiovascular death and heart failure hospitalization was reduced by 21%, which is highly statistically significant and clinically meaningful, noted Stefan Anker, MD, PhD, FESC, principal investigator of EMPEROR-Preserved.

There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized, stated Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.

There will be new ESC heart failure guidelines and presentation of data from EMPEROR-Preserved and EMPEROR-Pooled, noted Rudolf de Boer, MD, PhD, of University Medical Center Groningen, the Netherlands.

Krajowe Centrum ds AIDS (National AIDS Center) in Warsaw, Poland, was founded in 1993 as part of the country’s Ministry of Health. Its chief area of advocacy and outreach is access to antiretroviral treatment, in addition to new areas of focus that include prevention of sexually transmitted infections and hepatitis C virus.

Actinic keratosis outcomes can be affected by several variables, and these lesions need to be treated to minimize progression risk, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

Asociaţia Română Anti-SIDA (ARAS; Romanian Association Against AIDS) was founded on April 10, 1992, just 3 years after the fall of communism, making it the first such organization in the country following a time when HIV was not officially acknowledged nor prevention of HIV and sexually transmitted infections discussed.

We can safely delay excising in situ and early-stage melanomas while managing our patients’ care, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

The pandemic has exacerbated not only cardiovascular care, but also the mental health of patients, noted Mariana Garcia, MD, cardiology fellow in the Academic Clinical Investigator Pathway at Emory University and member of T32, Multidisciplinary Research Training to Reduce Inequalities in Cardiovascular Health (METRIC).

Providers need to put themselves in their patients' shoes and think about how they would like to receive services, emphasized Helen Bygrave, MD, chronic diseases advisor for the Médecins Sans Frontières’ (Doctors Without Borders) Access Campaign.

Patients should continue to be monitored while on treatment with SGLT2 inhibitors if they are being treated for comorbid type 2 diabetes and heart failure, emphasized Mikhail N. Kosiborod, MD, cardiologist, vice president of Research at Saint Luke's Health System.

Bobeck Modjtahedi, MD, highlights some of the challenges of using telehealth to treat individuals with diabetic retinopathy.

Adults living with HIV sometimes get lost, and we need to optimize their outcomes, noted Allison Agwu, MD, ScM, FAAP, FIDSA, Johns Hopkins University School of Medicine.

The characteristics of the tumor and the presence of surgical fatigue can help determine patients’ candidacy for skin cancer surgery, explained Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

Pediatric patients with atopic dermatitis (AD) often vary in disease severity and it can be difficult to assess how much of a topical therapy is needed, said Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego.

Barriers to authorship and adequate representation of women in heart failure–focused clinical trials need to be addressed, noted Mariana Garcia, MD, cardiology fellow in the Academic Clinical Investigator Pathway at Emory University and member of T32, Multidisciplinary Research Training to Reduce Inequalities in Cardiovascular Health (METRIC).